Search

Displaying results 3821 - 3830 of 4644 in total
  1. Drug

    EP-2104R

    go.drugbank.com/drugs/DB05675
    Experimental

    EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. It is the first targeted high-resolution technique designed to visualize blood clots directly. It is being developed by EPIX Pharmaceuticals, Inc.

  2. Drug

    FINLAY-FR-1

    go.drugbank.com/drugs/DB16524
    Experimental

    FINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute[L31373].

  3. Drug

    Linaprazan glurate

    go.drugbank.com/drugs/DB21534
    Investigational

    Linaprazan glurate is under investigation in clinical trial NCT07037875 (A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due

  4. Drug

    Relacatib

    go.drugbank.com/drugs/DB06367
    Investigational

  5. Drug

    Pentaerythritol tetranitrate

    go.drugbank.com/drugs/DB06154
    ApprovedWithdrawn

    It is recognized by the FDA to be a coronary vasodilator in the treatment of heart conditions such as angina [L2395].

    Synonyms: Tetranitrato de pentaeritritilo, Tetranitrate de pentaerithrityle
  6. Drug

    Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB16923
    Approved

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  7. Drug

    Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB18750
    Approved

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  8. Drug

    Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB22669
    Approved

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  9. Drug

    Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB22671
    Approved

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  10. Drug

    Influenza A virus A/Perth/722/2024 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB31654
    Approved

    Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.